Pluri Inc. — Investor Presentation 2015

May 19, 2015

==> picture [176 x 96] intentionally omitted <==

Pluristem to Conduct Conference at Tel Aviv Stock Exchange to Review Regulatory Progress and Company Strategy

HAIFA, ISRAEL, May 19, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced it will conduct a conference on Monday, May 25, 2015 at 8:30 AM, at the Tel Aviv Stock Exchange’s conference center. Pluristem’s executive management team will speak about the strategic importance of its latest regulatory progress including:

• European Medicines Agency’s selection of Pluristem’s PLX cell program in critical limb ischemia for the Adaptive Pathways pilot project.

• Japan's Pharmaceuticals and Medical Devices Agency consenting to the quality and manufacturing methods for PLX-PAD cells for use in clinical trials in Japan.

The conference agenda includes:

• I. Zami Aberman, Chairman & CEO

  • Mr. Aberman will present the current state of the cell therapy industry and developments that may impact its future.

• II. Dr. Esther Lukasiewicz Hagai, VP Clinical & Medical Affairs Dr. Hagai will describe the new regulatory pathways in Europe and Japan and discuss their implications for Pluristem’s clinical development programs.

• III. Yaky Yanay, President & COO

  • Mr. Yanay will speak regarding the strategic meaning of the accelerated pathways for Pluristem, upcoming milestones, and future plans.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary threedimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

{N0417185; 1}

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Contact:

Pluristem Therapeutics Inc. Efrat Kaduri Investor & Public Relations Manager +972-74-710-8721 efratk@Pluristem.com

Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com

{N0417185; 1}